Compare Enveric Biosciences Inc (ENVB) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.71 (market cap $3.14B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is far larger — about 461.8× Enveric Biosciences Inc's market cap, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| ENVB | SPHD | |
|---|---|---|
Market Cap | $6.80M | $3.14B |
Volume | 64,867 | 1,461,349 |
Sector | Health | — |
52-Week High | $10.80 | $53.55 |
52-Week Low | $1.27 | $46.96 |
Typical Hold Time | 14 Days | 125 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SPHD trades at $48.19, down 0.58% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income but facing criticism for weaker total returns compared to peers like SCHD. Recent dividends of $0.20 and $0.21 were declared for 2026, emphasizing its income-oriented strategy.
Outlook is cautious due to underperformance risks and lack of quality filters in stock selection. Opportunities include reliable monthly dividends for retirees, but risks involve yield traps and market volatility. Investors should weigh income needs against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
